GREATER COMBINED REDUCTIONS IN HbA 1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN...
GREATER COMBINED REDUCTIONS IN HbA 1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES
About this item
Full title
Author / Creator
Publisher
United States
Journal title
Language
English
Formats
Publication information
Publisher
United States
Subjects
More information
Scope and Contents
Contents
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog for the once-weekly treatment of type 2 diabetes (T2D). In the global SUSTAIN clinical trial program, semaglutide demonstrated superior glycated hemoglobin (HbA
) and body weight reductions versus comparators. This post hoc analysis compared the proportion of patients achieving combined red...
Alternative Titles
Full title
GREATER COMBINED REDUCTIONS IN HbA 1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_30865526
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_30865526
Other Identifiers
ISSN
1530-891X
DOI
10.4158/EP-2018-0444
